A Phase 2a, Randomized, Double-Blinded, Placebo-Controlled, Multicenter Study to Investigate the Antiviral Effect, Safety, Tolerability, and Pharmacokinetics of STP0404 in Adults With HIV-1 Infection
Latest Information Update: 10 Feb 2026
At a glance
- Drugs STP-0404 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Sponsors ST Pharm
Most Recent Events
- 06 Feb 2026 Planned End Date changed from 31 Dec 2025 to 30 Apr 2026.
- 06 Feb 2026 Planned primary completion date changed from 10 Dec 2025 to 10 Apr 2026.
- 02 Dec 2024 Planned End Date changed from 21 Nov 2024 to 31 Dec 2025.